Biotech Values

[DewDiligence]

Note that the old ABT (pre ABBV spinoff) wouldn’t have been able to engineer a tax inversion with SHPG because it was too large a company for SHPG to have met the 20% threshold for an inversion (even if the deal consideration had been 100% in stock).

Thus, there’s a side benefit to US-based companies getting smaller via corporate spin-offs that was rarely if ever discussed until the recent cascade of tax-inversion deals.

p.s. I will add the ABBV-SHPG merger to the table in #msg-104104101 when the terms become finalized.